Webinar Details:

Compounded sterile preparations (CSPs) with short beyond-use dates (BUDs)—typically preparations assigned immediate-use or ≤12/24-hour BUD categories under USP General Chapter <797>—present unique challenges for sterility assurance because traditional sterility testing (which requires 14-day incubation) cannot be completed before the product is administered or expires. This creates a fundamental tension between regulatory sterility verification and clinical urgency, particularly for emergency compounding, code-cart preparations, and time-critical infusions such as chemotherapy, parenteral nutrition, or STAT antibiotics.

This abstract examines the layered risk-mitigation strategies pharmacies use to assure sterility for short-dated CSPs in the absence of completed sterility testing. Primary controls include: (1) engineering controls—use of ISO Class 5 primary engineering controls (laminar airflow workbenches, biological safety cabinets, or compounding aseptic isolators) located within appropriately classified ISO 7/8 environments; (2) personnel qualification—garbing competency, hand hygiene, and media-fill testing performed at intervals mandated by risk level (immediate-use, Category 1, or Category 2 compounding); (3) environmental monitoring—viable and nonviable particle sampling, surface sampling, and periodic certification of primary and secondary engineering controls to establish ongoing process control; and (4) aseptic technique validation through direct observation and gloved fingertip/thumb sampling.

Because short BUDs preclude prospective sterility test results, sterility assurance instead relies on a "quality-by-design" and process-control model: sterility is inferred from a validated, controlled, and monitored compounding environment and process rather than confirmed by end-product testing. USP <797> stratifies BUDs according to compounding category (immediate-use, low-, medium-, and high-risk historically; now Category 1 and Category 2) and correspondingly restricts allowable storage time and temperature, shifting the burden of assurance toward process validation, environmental control, and personnel competency rather than retrospective microbiological confirmation.

Key discussion points include: the role of risk-level classification in determining permissible BUD windows; the limitations of endotoxin and rapid sterility methods (e.g., rapid microbial detection systems) as partial mitigants where feasible; the importance of a robust environmental monitoring program with trend analysis and excursion investigation; documentation and traceability practices that allow retrospective linkage of a dispensed CSP to a specific compounding event, personnel, and environmental conditions; and the necessity of a strong quality assurance program, including periodic media-fill revalidation and corrective action/preventive action (CAPA) protocols when environmental or personnel monitoring results fall outside acceptable limits.

Fee:
$385 for one person
$700 2-5 people
$999 6-10 people

Register for ECC-766